Navigation Links
IntelliCell BioSciences Files Patent Application for a New Mechanical Method to Separate Stromal Vascular Fraction from the Blood Vessels in Adipose Tissue
Date:8/21/2012

NEW YORK, Aug. 21, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has filed a patent application for a new mechanical method to separate stromal vascular fraction (SVF) from the blood vessels in adipose tissue (fat) to be used clinically in regenerative medicine.

The provisional patent, titled, "ISOLATION OF STROMAL VASCULAR FRACTION FROM THE BLOOD VESSELS IN ADIPOSE TISSUE USING HOMONOGENATION, A MECHANICAL METHOD" expands the patent portfolios of IntelliCell in mechanical methods to isolate/separate SVF from blood vessels in adipose tissue.

According to IntelliCell's Chairman/CEO Steven Victor MD, "This will strengthen our position in new and different methods of separation of SVF from the blood vessels in adipose tissue.  We feel that using a mechanical means of separation of SVF is superior to that by using enzymes since the time and cost are vastly reduced and you do not have to worry about endotoxins in the specimen.  I also believe by using mechanical methods of separation we fall within the 'minimally manipulated' guidelines of the FDA CFR 1271.10."

Sarah Young, Director of Quality Assurance stated, "This is another exciting discovery in that we have been able to take a technology and develop a protocol to separate SVF so we can have viable cells.  This is a significant advancement in the mechanical method of cell separation."

IntelliCell recognizes the future of cellular medicine in SVF therapy.  These are vascular cells residing in the walls of all blood vessels in the body and the IntelliCell process will soon harvest these cells from non-living adipose tissue. In the future as part of this homologous process,

Dr. Victor said, "The future of medicine has reached an exciting stage with the knowledge that SVF can be used clinically to treat patients for a number of disease states with high unmet clinical needs."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contacts:
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
(212) 843-9337  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
9. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
10. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):